Corbus Pharmaceuticals Hldgs Inc (CRBP)

$9.11 +0.21 (2.36%)
Market Cap 114.29M
Revenue (ttm) 0.00
Net Income (ttm) -40.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 93,287
Avg Vol 163,116
Day's Range N/A - N/A
Shares Out 12.24M
Stochastic %K 30%
Beta 3.20
Analysts Strong Sell
Price Target $42.89

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 963 0100
Fax: 617 663 6085
Address:
500 River Ridge Drive, Norwood, United States
JarvisFlow
JarvisFlow Aug. 6 at 12:30 PM
Oppenheimer has updated their rating for Corbus Pharmaceuticals ( $CRBP ) to Outperform with a price target of 53.
0 · Reply
Jckemp3
Jckemp3 Aug. 5 at 6:32 PM
$CRBP anyone have inflow/outflow numbers ?
0 · Reply
Estimize
Estimize Aug. 5 at 12:36 PM
$CRBP reported YoY revenue growth for Q2, in Q1. http://www.estimize.com/intro/crbp?chart=historical&metric_name=revenue&utm_content=CRB
0 · Reply
Geohotventures
Geohotventures Aug. 1 at 4:47 PM
$CRBP
0 · Reply
Cricket23
Cricket23 Aug. 1 at 3:53 PM
$CRBP All broad markets are in deep red and CRBP is up and in the green. LOVE to see it! There is definitely an uptrend being established and with a lot of positive news to be reported soon, we could easily see $20-30 very soon!
0 · Reply
shoagh12
shoagh12 Jul. 29 at 12:04 PM
$CRBP 20$ end of August
0 · Reply
Cricket23
Cricket23 Jul. 28 at 6:48 PM
$CRBP Very nice gain today from CRBP! Everyone needs to take a look at their website and look at the pipeline of products they have to offer. In my opinion, this company stock price is extremely low for the current and future value of what they are offering. Stock price will continue to increase as good news keep coming out. Company has a bright future ahead!
0 · Reply
MarkT87
MarkT87 Jul. 24 at 10:34 PM
$CRBP
0 · Reply
birdmine
birdmine Jul. 24 at 9:05 AM
$CRBP 👀👀👀😑😑😑😑
0 · Reply
shoagh12
shoagh12 Jul. 23 at 2:46 PM
$CRBP 15 soon
0 · Reply
Latest News on CRBP
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 25, 2025, 8:00 AM EDT - 6 weeks ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 24, 2025, 4:05 PM EDT - 6 weeks ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

Jun 17, 2025, 3:42 PM EDT - 7 weeks ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Mar 28, 2025, 8:00 AM EDT - 4 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 14, 2025, 7:30 AM EST - 6 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Feb 11, 2025, 7:30 AM EST - 6 months ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 8:00 AM EST - 6 months ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 7 months ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Dec 9, 2024, 7:00 AM EST - 8 months ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Dec 3, 2024, 7:00 AM EST - 8 months ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Nov 11, 2024, 4:12 AM EST - 9 months ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 29, 2024, 8:00 AM EDT - 10 months ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Oct 16, 2024, 8:00 AM EDT - 10 months ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 26, 2024, 8:00 AM EDT - 11 months ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Sep 23, 2024, 2:01 PM EDT - 11 months ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 30, 2024, 8:50 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 3, 2024, 1:03 PM EDT - 1 year ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

Jun 1, 2024, 10:00 AM EDT - 1 year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 23, 2024, 5:05 PM EDT - 1 year ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 9, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

May 1, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Mar 6, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 28, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 9:50 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 2, 2024, 4:01 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Corbus Pharmaceuticals Announces Pricing of Public Offering

Jan 31, 2024, 9:19 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals Announces Proposed Public Offering

Jan 30, 2024, 6:55 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 30, 2024, 7:13 AM EST - 1 year ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 2:17 PM EST - 1 year ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

Jan 29, 2024, 7:18 AM EST - 1 year ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Jan 26, 2024, 7:30 AM EST - 1 year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Jan 23, 2024, 8:00 AM EST - 1 year ago

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Jan 9, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Dec 18, 2023, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

JarvisFlow
JarvisFlow Aug. 6 at 12:30 PM
Oppenheimer has updated their rating for Corbus Pharmaceuticals ( $CRBP ) to Outperform with a price target of 53.
0 · Reply
Jckemp3
Jckemp3 Aug. 5 at 6:32 PM
$CRBP anyone have inflow/outflow numbers ?
0 · Reply
Estimize
Estimize Aug. 5 at 12:36 PM
$CRBP reported YoY revenue growth for Q2, in Q1. http://www.estimize.com/intro/crbp?chart=historical&metric_name=revenue&utm_content=CRB
0 · Reply
Geohotventures
Geohotventures Aug. 1 at 4:47 PM
$CRBP
0 · Reply
Cricket23
Cricket23 Aug. 1 at 3:53 PM
$CRBP All broad markets are in deep red and CRBP is up and in the green. LOVE to see it! There is definitely an uptrend being established and with a lot of positive news to be reported soon, we could easily see $20-30 very soon!
0 · Reply
shoagh12
shoagh12 Jul. 29 at 12:04 PM
$CRBP 20$ end of August
0 · Reply
Cricket23
Cricket23 Jul. 28 at 6:48 PM
$CRBP Very nice gain today from CRBP! Everyone needs to take a look at their website and look at the pipeline of products they have to offer. In my opinion, this company stock price is extremely low for the current and future value of what they are offering. Stock price will continue to increase as good news keep coming out. Company has a bright future ahead!
0 · Reply
MarkT87
MarkT87 Jul. 24 at 10:34 PM
$CRBP
0 · Reply
birdmine
birdmine Jul. 24 at 9:05 AM
$CRBP 👀👀👀😑😑😑😑
0 · Reply
shoagh12
shoagh12 Jul. 23 at 2:46 PM
$CRBP 15 soon
0 · Reply
Cricket23
Cricket23 Jul. 21 at 5:34 PM
$CRBP Nice move we are seeing today from CRBP to the upside. I do love the company's current and future pipeline of products because there is great value involved with it. The company has a lot of cash on hand to fund operations and a lot of positive news coming out very soon. Any mention of positive news will send the stock price climbing much higher towards that $20-30 mark. Holding Strong!
0 · Reply
silentmaxx
silentmaxx Jul. 21 at 3:06 PM
$CRBP
0 · Reply
birdmine
birdmine Jul. 21 at 2:17 PM
$CRBP is this about to be a blessing?!
0 · Reply
justme_DC
justme_DC Jul. 20 at 8:41 PM
$CRBP I liked their price to book, 11 days to cover and the analysts PT....but Blackrock dumping a majority of their shares makes me reconsider. Often wise to follow the money of the big players. Hard decisions Monday GL to all
0 · Reply
birdmine
birdmine Jul. 18 at 1:09 PM
$CRBP keeps flirting with 9$ like they’re at a club or something!!
0 · Reply
MakeThingsFly
MakeThingsFly Jul. 17 at 12:15 AM
$CRBP https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0002052113-25-002503/primary_doc.html
0 · Reply
MakeThingsFly
MakeThingsFly Jul. 17 at 12:07 AM
$CRBP BlackRock just picked up about 350,000 shares (2.9%). Looking forward to the end of Q3 and 2026!!
1 · Reply
justme_DC
justme_DC Jul. 16 at 7:41 PM
$CRBP Would so love a positive / substantive PR right about NOW
0 · Reply
eaglesflyhi
eaglesflyhi Jul. 16 at 5:40 PM
$JDZG do a $CRBP who post split eventually ran to $60+
0 · Reply
BuyHighSellLow4Life
BuyHighSellLow4Life Jul. 15 at 1:20 PM
$CRBP liking this action, keep it up you POS
0 · Reply
BuyHighSellLow4Life
BuyHighSellLow4Life Jul. 9 at 2:58 PM
$CRBP green dildo let’s go
0 · Reply
justme_DC
justme_DC Jul. 2 at 8:01 PM
$CRBP This is the one exception where I take strong notice of SI. With ~11 days to cover, wow wouldn't it be nice for some unexpected positive catalyst to be announced. Great day though regardless....I will take it!
0 · Reply